CD38 and neoplasm: Besides T cells and NK cells, CD38 is also expressed on dendritic cells and can induce a Th1 response [115,116], again highlighting a potentially anti-tumor immune population that may be inhibited with CD38 targeting and complicate treatment efficacy.